JP2019513151A - カンプトテシン誘導体及びその使用 - Google Patents

カンプトテシン誘導体及びその使用 Download PDF

Info

Publication number
JP2019513151A
JP2019513151A JP2018567008A JP2018567008A JP2019513151A JP 2019513151 A JP2019513151 A JP 2019513151A JP 2018567008 A JP2018567008 A JP 2018567008A JP 2018567008 A JP2018567008 A JP 2018567008A JP 2019513151 A JP2019513151 A JP 2019513151A
Authority
JP
Japan
Prior art keywords
compound
hydrogen
alkyl
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018567008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513151A5 (OSRAM
Inventor
ピーター ランゲッカー，
ピーター ランゲッカー，
マティアス シュタイアート，
マティアス シュタイアート，
トシアキ ヒノ，
トシアキ ヒノ，
ジャン シチンクシ，
ジャン シチンクシ，
クマラパンディアン ポールヴァナン，
クマラパンディアン ポールヴァナン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Los Gatos Pharmaceuticals Inc
Paulvannan Kumarapandian
Scicinksi Jan
Original Assignee
Los Gatos Pharmaceuticals Inc
Paulvannan Kumarapandian
Scicinksi Jan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Gatos Pharmaceuticals Inc, Paulvannan Kumarapandian, Scicinksi Jan filed Critical Los Gatos Pharmaceuticals Inc
Publication of JP2019513151A publication Critical patent/JP2019513151A/ja
Publication of JP2019513151A5 publication Critical patent/JP2019513151A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018567008A 2016-03-08 2017-03-08 カンプトテシン誘導体及びその使用 Pending JP2019513151A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305519P 2016-03-08 2016-03-08
US62/305,519 2016-03-08
PCT/US2017/021440 WO2017156183A1 (en) 2016-03-08 2017-03-08 Camptothecin derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2019513151A true JP2019513151A (ja) 2019-05-23
JP2019513151A5 JP2019513151A5 (OSRAM) 2020-04-09

Family

ID=59786227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567008A Pending JP2019513151A (ja) 2016-03-08 2017-03-08 カンプトテシン誘導体及びその使用

Country Status (4)

Country Link
US (1) US10407437B2 (OSRAM)
EP (1) EP3426352A4 (OSRAM)
JP (1) JP2019513151A (OSRAM)
WO (1) WO2017156183A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500350A (ja) * 2006-08-11 2010-01-07 ザ クリストゥス ステーリン ファウンデーション フォー キャンサー リサーチ カンプトテシンのエステルの製造法
JP2012518636A (ja) * 2009-02-20 2012-08-16 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
JP2019510085A (ja) * 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
EP1007012A4 (en) 1996-10-01 2006-01-18 Cima Labs Inc TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6267983B1 (en) 1997-10-28 2001-07-31 Bando Chemical Industries, Ltd. Dermatological patch and process for producing thereof
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
IN191203B (OSRAM) 1999-02-17 2003-10-04 Amarnath Prof Maitra
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
DE10008904A1 (de) 2000-02-25 2001-09-06 Degussa Verfahren zur Rückgewinnung von Katalysator-Übergangsmetallen aus salzhaltigen Reaktionsgemischen
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6579519B2 (en) 2000-09-18 2003-06-17 Registrar, University Of Delhi Sustained release and long residing ophthalmic formulation and the process of preparing the same
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6834791B2 (en) 2002-01-24 2004-12-28 Nas Interplex Inc. Solder-bearing components and method of retaining a solder mass therein
WO2008085556A2 (en) 2006-09-12 2008-07-17 University Of South Florida Surfactant-free nanoparticles for drug delivery
RU2492872C2 (ru) 2006-10-05 2013-09-20 Дзе Джонс Хопкинс Юниверсити Вододиспергируемые пероральные, парентеральные и местные композиции для плохо растворимых в воде лекарственных препаратов, включающие улучшающие их свойства полимерные наночастицы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500350A (ja) * 2006-08-11 2010-01-07 ザ クリストゥス ステーリン ファウンデーション フォー キャンサー リサーチ カンプトテシンのエステルの製造法
JP2012518636A (ja) * 2009-02-20 2012-08-16 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
JP2019510085A (ja) * 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BALA, VASKOR ET AL.: "Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy", MOLECULAR PHARMACEUTICS, vol. 13, JPN6021000898, 1 December 2015 (2015-12-01), pages 287 - 294, ISSN: 0004574199 *

Also Published As

Publication number Publication date
US10407437B2 (en) 2019-09-10
US20170260194A1 (en) 2017-09-14
EP3426352A1 (en) 2019-01-16
EP3426352A4 (en) 2019-11-13
WO2017156183A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
JP6856532B2 (ja) エルゴリン化合物およびその使用
US8604035B2 (en) Fluoroergoline analogs
JP2016503795A (ja) 新規メチセルジド誘導体
JP2016503796A (ja) フルオロエルゴリン誘導体およびその使用
JP2015525239A (ja) 新規カベルゴリン誘導体
US9012640B2 (en) Cabergoline derivatives
US8946420B2 (en) Neuromodulatory compounds
US8722699B2 (en) Iso-ergoline derivatives
JP2018502889A (ja) イソエルゴリン化合物およびその使用
JP2019513151A (ja) カンプトテシン誘導体及びその使用
US10106521B2 (en) Eckol derivatives, methods of synthesis and uses thereof
JP5840143B2 (ja) ニコチン性アセチルコリン受容体モジュレーター
US20250017910A1 (en) 2-Thioxothiazolidine-4-One Derivatives And Their Uses
US12017997B2 (en) Host-targeted pan-respiratory antiviral small molecule therapeutics
US20240300905A1 (en) Quinazoline Compounds and Uses
JP2025501308A (ja) 非環式チオールプロドラッグ
WO2024238794A9 (en) Phenol prodrugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210819